Attenuation of toll-like receptor 2-mediated innate immune response in patients with alcoholic chronic liver disease

Liver International

Volumn 30, Issue 7, 2010, Pages 1003-1011

  Pimentel Nunes, Pedro ^a,b   Roncon Albuquerque, Roberto ^a   Gonçalves, Nádia ^a   Fernandes Cerqueira, Cátia ^a   Cardoso, Hélder ^c   Bastos, Rui Pedro ^c   Marques, Margarida ^c   Marques, Cristina ^c   Alexandre Sarmento, José ^c   Costa Santos, Carlos ^c   Macedo, Guilherme ^c   Pestana, Manuel ^a   Dinis Ribeiro, Mário ^a,b   Leite Moreira, Adelino F ^a  

^a University of Porto   (Portugal)

^b PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^c HOSPITAL DE SÃO JOÃO   (Portugal)

Author keywords

Alcohol; Infection; Innate immunity receptors; Liver disease; TLR2; TLR4

Indexed keywords

CD14 ANTIGEN; INTERLEUKIN 10; LIPOPOLYSACCHARIDE; LIPOPOLYSACCHARIDE BINDING PROTEIN; MESSENGER RNA; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 6; TUMOR NECROSIS FACTOR ALPHA; ZYMOSAN; ACUTE PHASE PROTEIN; CARRIER PROTEIN; IL10 PROTEIN, HUMAN; LIPOPEPTIDE; LIPOPOLYSACCHARIDE-BINDING PROTEIN; MEMBRANE PROTEIN; TLR2 PROTEIN, HUMAN; TLR4 PROTEIN, HUMAN;

ADULT; ALCOHOL LIVER DISEASE; ARTICLE; CELL CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; EX VIVO STUDY; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; INNATE IMMUNITY; MALE; MONOCYTE; PROTEIN DETERMINATION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; AGONISTS; BLOOD; CASE CONTROL STUDY; CHRONIC DISEASE; DOWN REGULATION; DRUG EFFECTS; GENE EXPRESSION PROFILING; GENETICS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; PORTUGAL;

ACUTE-PHASE PROTEINS; ANTIGENS, CD14; CARRIER PROTEINS; CASE-CONTROL STUDIES; CELLS, CULTURED; CHRONIC DISEASE; DOWN-REGULATION; GENE EXPRESSION PROFILING; HUMANS; IMMUNITY, INNATE; INTERLEUKIN-10; LEUKOCYTES, MONONUCLEAR; LIPOPEPTIDES; LIPOPOLYSACCHARIDES; LIVER DISEASES, ALCOHOLIC; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PORTUGAL; RNA, MESSENGER; TOLL-LIKE RECEPTOR 2; TOLL-LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR-ALPHA; ZYMOSAN;

EID: 77957132282     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2010.02251.x     Document Type: Article

References (57)

1. Carithers RL, Mcclain C. Alcoholic liver disease. Sleisenger and Fordtran's Gastrointestinal and Liver Disease 2006, 1771-92. Feldman L, Friedman LBrandt J. In, eds, 8th edn
2. Christou L, Pappas G, Falagas ME. Bacterial infection-related morbidity and mortality in cirrhosis. Am J Gastroenterol 2007, 102:1510-7.
3. Caruntu FA, Benea L. Spontaneous bacterial peritonitis: pathogenesis, diagnosis, treatment. J Gastrointestin Liver Dis 2006, 15:51-6.
4. Garcia-Tsao G. Bacterial infections in cirrhosis: treatment and prophylaxis. J Hepatol 2005, 42((Suppl. 1)):S85-92.
5. Garcia-Tsao G, Wiest R. Gut microflora in the pathogenesis of the complications of cirrhosis. Best Pract Res Clin Gastroenterol 2004, 18:353-72.
6. Wiest R, Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. Hepatology 2005, 41:422-33.
7. Fiuza C, Salcedo M, Clemente G, Tellado JM. In vivo neutrophil dysfunction in cirrhotic patients with advanced liver disease. J Infect Dis 2000, 182:526-33.
8. Trevisani F, Castelli E, Foschi FG. Impaired tuftsin activity in cirrhosis: relationship with splenic function and clinical outcome. Gut 2002, 50:707-12.
9. Homann C, Varming K, Hogasen K. Acquired C3 deficiency in patients with alcoholic cirrhosis predisposes to infection and increased mortality. Gut 1997, 40:544-9.
10. Gomez F, Ruiz P, Schreiber AD. Impaired function of macrophage Fc gamma receptors and bacterial infection in alcoholic cirrhosis. N Engl J Med 1994, 331:1122-8.
11. Ono Y, Watanabe T, Matsumoto K. Opsonophagocytic dysfunction in patients with liver cirrhosis and low responses to tumor necrosis factor-alpha and lipopolysaccharide in patients' blood. J Infect Chemother 2004, 10:200-7.
12. Mcclain CJ, Song Z, Barve SS, Hill DB, Deaciuc I. Recent advances in alcoholic liver disease. IV. Dysregulated cytokine metabolism in alcoholic liver disease. Am J Physiol Gastrointest Liver Physiol 2004, 287:G497-502.
13. Scott JD, Garland N. Chronic liver disease in Aboriginal North Americans. World J Gastroenterol 2008, 14:4607-15.
14. Macgregor RR. Alcohol and immune defense. JAMA 1986, 256:1474-9.
15. Nelson S, Kolls JK. Alcohol, host defence and society. Nat Rev Immunol 2002, 2:205-9.
16. Frank J, Witte K, Schrodl W, Schutt C. Chronic alcoholism causes deleterious conditioning of innate immunity. Alcohol Alcohol 2004, 39:386-92.
17. Laso FJ, Vaquero JM, Almeida J, Marcos M, Orfao A. Production of inflammatory cytokines by peripheral blood monocytes in chronic alcoholism: relationship with ethanol intake and liver disease. Cytometry B Clin Cytom 2007, 72:408-15.
18. Medzhitov R, Janeway C. Innate immunity. N Engl J Med 2000, 343:338-44.
19. Rock FL, Hardiman G, Timans JC, Kastelein RA, Bazan JF. A family of human receptors structurally related to Drosophila Toll. Proc Natl Acad Sci USA 1998, 95:588-93.
20. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003, 21:335-76.
21. O'Mahony DS, Pham U, Iyer R, Hawn TR, Liles WC. Differential constitutive and cytokine-modulated expression of human Toll-like receptors in primary neutrophils, monocytes, and macrophages. Int J Med Sci 2008, 5:1-8.
22. Fearon DT. Seeking wisdom in innate immunity. Nature 1997, 388:323-4.
23. Harris G, Kuolee R, Chen W. Role of Toll-like receptors in health and diseases of gastrointestinal tract. World J Gastroenterol 2006, 12:2149-60.
24. Takeuchi O, Hoshino K, Kawai T. Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components. Immunity 1999, 11:443-51.
25. Yoshimura A, Lien E, Ingalls RR. Cutting edge: recognition of Gram-positive bacterial cell wall components by the innate immune system occurs via Toll-like receptor 2. J Immunol 1999, 163:1-5.
26. Kaisho T, Akira S. Pleiotropic function of Toll-like receptors. Microbes Infect 2004, 6:1388-94.
27. Zhang D, Zhang G, Hayden MS. A toll-like receptor that prevents infection by uropathogenic bacteria. Science 2004, 303:1522-6.
28. Erridge C, Pridmore A, Eley A, Stewart J, Poxton IR. Lipopolysaccharides of Bacteroides fragilis, Chlamydia trachomatis and Pseudomonas aeruginosa signal via toll-like receptor 2. J Med Microbiol 2004, 53((Part. 8)):735-40.
29. Farhat K, Riekenberg S, Heine H. Heterodimerization of TLR2 with TLR1 or TLR6 expands the ligand spectrum but does not lead to differential signaling. J Leukoc Biol 2008, 83:692-701.
30. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004, 4:499-511.
31. Wetzler LM. The role of Toll-like receptor 2 in microbial disease and immunity. Vaccine 2003, 21((Suppl. 2)):S55-60.
32. Fukata M, Chen A, Klepper A. Cox-2 is regulated by Toll-like receptor-4 (TLR4) signaling: role in proliferation and apoptosis in the intestine. Gastroenterology 2006, 131:862-77.
33. Kopp E, Medzhitov R. Recognition of microbial infection by Toll-like receptors. Curr Opin Immunol 2003, 15:396-401.
34. O'Neill LA, Dunne A, Edjeback M. Mal and MyD88: adapter proteins involved in signal transduction by Toll-like receptors. J Endotoxin Res 2003, 9:55-9.
35. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973, 60:646-9.
36. Manigold T, Bocker U, Hanck C. Differential expression of toll-like receptors 2 and 4 in patients with liver cirrhosis. Eur J Gastroenterol Hepatol 2003, 15:275-82.
37. Riordan SM, Skinner N, Nagree A. Peripheral blood mononuclear cell expression of toll-like receptors and relation to cytokine levels in cirrhosis. Hepatology 2003, 37:1154-64.
38. Tazi KA, Quioc JJ, Saada V. Upregulation of TNF-alpha production signaling pathways in monocytes from patients with advanced cirrhosis: possible role of Akt and IRAK-M. J Hepatol 2006, 45:280-9.
39. Lin CY, Tsai IF, Ho YP. Endotoxemia contributes to the immune paralysis in patients with cirrhosis. J Hepatol 2007, 46:816-26.
40. Stadlbauer V, Mookerjee RP, Hodges S. Effect of probiotic treatment on deranged neutrophil function and cytokine responses in patients with compensated alcoholic cirrhosis. J Hepatol 2008, 48:945-51.
41. Testro AG, Gow PJ, Angus PW. Effects of antibiotics on expression and function of Toll-like receptors 2 and 4 on mononuclear cells in patients with advanced cirrhosis. J Hepatol 2010, 52:199-205.
42. Wasmuth HE, Kunz D, Yagmur E. Patients with acute on chronic liver failure display " sepsis-like" immune paralysis. J Hepatol 2005, 42:195-201.
43. Urbaschek R, Mccuskey RS, Rudi V. Endotoxin, endotoxin-neutralizing-capacity, sCD14, sICAM-1, and cytokines in patients with various degrees of alcoholic liver disease. Alcohol Clin Exp Res 2001, 25:261-8.
44. Fukui H, Brauner B, Bode JC, Bode C. Plasma endotoxin concentrations in patients with alcoholic and non-alcoholic liver disease: reevaluation with an improved chromogenic assay. J Hepatol 1991, 12:162-9.
45. Lin RS, Lee FY, Lee SD. Endotoxemia in patients with chronic liver diseases: relationship to severity of liver diseases, presence of esophageal varices, and hyperdynamic circulation. J Hepatol 1995, 22:165-72.
46. Oesterreicher C, Pfeffel F, Petermann D, Muller C. Increased in vitro production and serum levels of the soluble lipopolysaccharide receptor sCD14 in liver disease. J Hepatol 1995, 23:396-402.
47. Andus T, Bauer J, Gerok W. Effects of cytokines on the liver. Hepatology 1991, 13:364-75.
48. Khoruts A, Stahnke L, Mcclain CJ, Logan G, Allen JI. Circulating tumor necrosis factor, interleukin-1 and interleukin-6 concentrations in chronic alcoholic patients. Hepatology 1991, 13:267-76.
49. Tilg H, Wilmer A, Vogel W. Serum levels of cytokines in chronic liver diseases. Gastroenterology 1992, 103:264-74.
50. Mcclain CJ, Barve S, Deaciuc I, Kugelmas M, Hill D. Cytokines in alcoholic liver disease. Semin Liver Dis 1999, 19:205-19.
51. Kitchens RL, Thompson PA. Modulatory effects of sCD14 and LBP on LPS-host cell interactions. J Endotoxin Res 2005, 11:225-9.
52. Kitchens RL, Thompson PA, Viriyakosol S, O'Keefe GE, Munford RS. Plasma CD14 decreases monocyte responses to LPS by transferring cell-bound LPS to plasma lipoproteins. J Clin Invest 2001, 108:485-93.
53. Vreugdenhil AC, Snoek AM, van'T Veer C, Greve JW, Buurman WA. LPS-binding protein circulates in association with apoB-containing lipoproteins and enhances endotoxin-LDL/VLDL interaction. J Clin Invest 2001, 107:225-34.
54. von Baehr V, Docke WD, Plauth M. Mechanisms of endotoxin tolerance in patients with alcoholic liver cirrhosis: role of interleukin 10, interleukin 1 receptor antagonist, and soluble tumour necrosis factor receptors as well as effector cell desensitisation. Gut 2000, 47:281-7.
55. Hirschfeld M, Kirschning CJ, Schwandner R. Cutting edge: inflammatory signaling by Borrelia burgdorferi lipoproteins is mediated by toll-like receptor 2. J Immunol 1999, 163:2382-6.
56. Ingalls RR, Lien E, Golenbock DT. Membrane-associated proteins of a lipopolysaccharide-deficient mutant of Neisseria meningitidis activate the inflammatory response through toll-like receptor 2. Infect Immun 2001, 69:2230-6.
57. Schwandner R, Dziarski R, Wesche H, Rothe M, Kirschning CJ. Peptidoglycan- and lipoteichoic acid-induced cell activation is mediated by toll-like receptor 2. J Biol Chem 1999, 274:17406-9.